Nanobodies as therapeutics: big opportunities for small antibodies

S Steeland, RE Vandenbroucke, C Libert - Drug discovery today, 2016 - Elsevier
Highlights•Nanobodies (Nbs) are camelid-derived single-domain antibodies.•Nbs have
powerful binding and inhibitory capacity with great therapeutic potential.•Nbs are used in …

Update on implications and mechanisms of angiogenesis in liver fibrosis

Z Zhang, F Zhang, Y Lu, S Zheng - Hepatology Research, 2015 - Wiley Online Library
Liver fibrosis occurs as a compensatory response to the process of tissue repair in a wide
range of chronic liver injures. It is characterized by excessive deposition of extracellular …

Development of a mono‐specific anti‐VEGF bivalent nanobody with extended plasma half‐life for treatment of pathologic neovascularization

A Sadeghi, M Behdani, S Muyldermans… - Drug testing and …, 2020 - Wiley Online Library
Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis within solid
cancers. Thus, targeting VEGF might be part of a feasible therapy for treating pathological …

Development of a recombinant camelid specific diabody against the heminecrolysin fraction of Hemiscorpius lepturus scorpion

M Bagheri, E Babaei, D Shahbazzadeh… - Toxin …, 2017 - Taylor & Francis
Scorpion sting is one of the most important problems in public health practice in many
countries. Khuzestan yellow scorpion, scientifically known as Hemiscorpius lepturus …

Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization

E Alirahimi, A Ashkiyan, F Kazemi-Lomedasht… - Cancer gene …, 2017 - nature.com
Angiogenesis is among the most important mechanisms that helps cancer cells to survive,
grow and undergo metastasis. Therefore, inhibiting angiogenesis will suppress tumor …

Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates

A Shoari, M Tahmasebi, F Khodabakhsh… - International …, 2022 - Elsevier
Solid cancers are affiliate on angiogenesis for preservation. The FDA-approved monoclonal
antibodies like Bevacizumab are currently being administered effectively as inhibitors of …

A conformation-based phage-display panning to screen neutralizing anti-VEGF VHHs with VEGFR2 mimicry behavior

SS Shahangian, RH Sajedi, S Hasannia, S Jalili… - International journal of …, 2015 - Elsevier
The potency of VEGF-based anti-angiogenic strategies in cancer therapy and the brilliant
characteristics of VHHs motivated us to directly block VEGF binding to its receptor with …

Development of a highly‐potent anti‐angiogenic VEGF8–109 heterodimer by directed blocking of its VEGFR‐2 binding site

F Ghavamipour, SS Shahangian, RH Sajedi… - The FEBS …, 2014 - Wiley Online Library
Angiogenesis is a hallmark of various pathological conditions and is controlled by a variety
of angiogenic factors. Blockade of vascular endothelial growth factor (VEGF) as the most …

[HTML][HTML] Designing and development of a tandem bivalent nanobody against VEGF165

F Khodabakhsh, M Salimian, P Ziaee… - Avicenna Journal of …, 2021 - ncbi.nlm.nih.gov
Background: Inhibition of angiogenesis using monoclonal antibodies is an effective strategy
in cancer therapy. However, they could not penetrate sufficiently into solid tumors. Antibody …

A novel method for endothelial cell isolation

Q Mao, X Huang, J He, W Liang… - Oncology …, 2016 - spandidos-publications.com
The present study aimed to develop a quick and efficient method for purification of newborn
endothelial cells from tumor tissues. Fresh tissues were separated from C57BL/6 mice …